Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Basic & clinical pharmacology & toxicology - 1 Oct 2017

Parra-Guillen Zinnia P, Berger Peter B, Haschke Manuel, Donzelli Massimiliano, Winogradova Daria, Pfister Bogumila, Früh Martin, Gillessen Silke, Krähenbühl Stephan, Kloft Charlotte, Joerger Markus

Abstract excerpt

Erlotinib is metabolized by cytochrome p450 (CYP) 3A and CYP1A. This study assessed CYP3A4 (midazolam) and CYP1A2 (caffeine) phenotyping in plasma and dried blood spots (DBS) for predicting the pharmacokinetics and toxicity of erlotinib in 36 patients with advanced NSCLC. On day 1, erlotinib 150 mg OD was initiated, and the two oral probe drugs midazolam (2 mg) and caffeine (100 mg) were added on day 1. Plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caffeine
Share to Chromatography, Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP1A2

Share to Dried Blood Spot Testing

Share to Drug Monitoring

Share to Erlotinib Hydrochloride

Share to Midazolam

Share to Pharmacogenomic Variants

Source

Identifiers

PMID: 28444958
DOI: 10.1111/bcpt.12801

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.PMID 28444958Read ↗

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.Semantic proximity Read ↗

Drug-induced effects on erlotinib metabolism.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

Evaluation of the Effect of Ritlecitinib on the Pharmacokinetics of Caffeine in Healthy ParticipantsSemantic proximity Read ↗

An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.Semantic proximity Read ↗

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.Semantic proximity Read ↗

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Semantic proximity Read ↗

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Semantic proximity Read ↗

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.